产品编号：GM-81151AB
产品名称：Anti-ALPPL2-MMAE ADC(Dar4)[SGN-ALPV]
目录价：询价
产品编号：GM-81151AB
产品名称：Anti-ALPPL2-MMAE ADC(Dar4)[SGN-ALPV]
目录价：询价
GM-81151AB-100 100μg
GM-81151AB-1mg 1mg
Expression System CHO
Purity >95% as determined by SDS-PAGE
Aggregation < 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR) 4.0
Endotoxin <1 EU/mg
Sterility 0.22 μm Filtered
Target ALPPL2
Clone SGN-ALPV
Alternative Names ALPPL, ALPPL2, GCAP
Source/lsotype Monoclonal Human IgG1(KDEL), κ
Application Positive control of Cytotoxicity Assay
Description SGN-ALPV is a novel investigational vedotin antibody–drug conjugate composed of a humanized anti-ALPP/ALPPL2 monoclonal antibody, a protease-cleavable linker, and the microtubule disrupting agent monomethyl auristatin E (MMAE). The proposed mechanism of action of SGN-ALPV is binding to ALPP/ALPPL2 on the cell surface, where it is internalized and trafficked to the lysosome. Lysosomal proteases cleave the linker to release MMAE into the cytoplasm, where it binds and disrupts the microtubule network, causing cell cycle arrest and apoptosis.
Formulation 20 mM Histidine, pH 6.0
Storage temp. Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
产品编号：GM-81151AB
产品名称：Anti-ALPPL2-MMAE ADC(Dar4)[SGN-ALPV]
目录价：询价
产品编号：GM-81151AB
产品名称：Anti-ALPPL2-MMAE ADC(Dar4)[SGN-ALPV]
目录价：询价
GM-81151AB-100 100μg
GM-81151AB-1mg 1mg
GM-81151AB-100 100μg
GM-81151AB-1mg 1mg
Expression System CHO
Purity >95% as determined by SDS-PAGE
Aggregation < 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR) 4.0
Endotoxin <1 EU/mg
Sterility 0.22 μm Filtered
Target ALPPL2
Clone SGN-ALPV
Alternative Names ALPPL, ALPPL2, GCAP
Source/lsotype Monoclonal Human IgG1(KDEL), κ
Application Positive control of Cytotoxicity Assay
Description SGN-ALPV is a novel investigational vedotin antibody–drug conjugate composed of a humanized anti-ALPP/ALPPL2 monoclonal antibody, a protease-cleavable linker, and the microtubule disrupting agent monomethyl auristatin E (MMAE). The proposed mechanism of action of SGN-ALPV is binding to ALPP/ALPPL2 on the cell surface, where it is internalized and trafficked to the lysosome. Lysosomal proteases cleave the linker to release MMAE into the cytoplasm, where it binds and disrupts the microtubule network, causing cell cycle arrest and apoptosis.
Formulation 20 mM Histidine, pH 6.0
Storage temp. Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
Expression System CHO
Purity >95% as determined by SDS-PAGE
Aggregation < 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR) 4.0
Endotoxin <1 EU/mg
Sterility 0.22 μm Filtered
Target ALPPL2
Clone SGN-ALPV
Alternative Names ALPPL, ALPPL2, GCAP
Source/lsotype Monoclonal Human IgG1(KDEL), κ
Application Positive control of Cytotoxicity Assay
Description SGN-ALPV is a novel investigational vedotin antibody–drug conjugate composed of a humanized anti-ALPP/ALPPL2 monoclonal antibody, a protease-cleavable linker, and the microtubule disrupting agent monomethyl auristatin E (MMAE). The proposed mechanism of action of SGN-ALPV is binding to ALPP/ALPPL2 on the cell surface, where it is internalized and trafficked to the lysosome. Lysosomal proteases cleave the linker to release MMAE into the cytoplasm, where it binds and disrupts the microtubule network, causing cell cycle arrest and apoptosis.
Formulation 20 mM Histidine, pH 6.0
Storage temp. Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
